The European Commission cleared the merger of pharmaceutical company Mylan with Pfizer’s Upjohn division, which operates Pfizer’s established generic and off-patent branded medicines (including products sold under the brands Viagra, Xanax and Lipitor). The merger was cleared in phase 1, subject to a number of divestments. A press release from Mylan indicates that the EC clearance constitutes a significant milestone: “We appreciate the opportunity to have worked collaboratively with the EC on this approval, and the scale and scope of these required product divestitures are substantially in line with Mylan’s previously stated expectations.”
A CRA team including Raphaël De Coninck, Christoph von Muellern and Séamus O’Donovan provided economic advice and support to Mylan.
For more details, please see the European Commission’s press release, here.